Favorable Response to Olaparib in a Patient with Cancer of Unknown Primary Carrying a Germline BRCA1 R71K Mutation
Xiaomeng Jia,1,* Shanshan Zhao,1,* Xiang Li,2,* Li Lv,3,* Xin Chen,4 Evenki Pan,4 Qiuxiang Ou,4 Chen Song,1 Siwen Sun,1 Jinbo Zhao,1 Lingzhi Xu,1 Man Li1 1Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, 116023, People’s Republic of Ch...
Guardado en:
Autores principales: | Jia X, Zhao S, Li X, Lv L, Chen X, Pan E, Ou Q, Song C, Sun S, Zhao J, Xu L, Li M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8b977021a23b4cf2ac1b1253421e1d8a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions
por: Yifan Su, et al.
Publicado: (2021) -
BRCA1 and BRCA2mutations in breast cancer patients from Venezuela
por: Lara,Karlena, et al.
Publicado: (2012) -
Analysis of 5382insC (BRCA1) and 6174delT (BRCA2) mutations in 382 healthy Chilean women with a family history of breast cancer
por: JARA,LILIAN, et al.
Publicado: (2002) -
Olaparib nanoparticles potentiated radiosensitization effects on lung cancer
por: Wu M, et al.
Publicado: (2018) -
Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform
por: Editorial Board
Publicado: (2021)